Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 765

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study

Open access
Gautret, Philippe, Lagier, Jean-Christophe, Parola, Philippe, Hoang, Van Thuan, Meddeb, Line, Sevestre, Jacques, Mailhe, Morgane, Doudier, Barbara, Aubry, Camille, Amrane, Sophie, Seng, Piseth, Hocquart, Marie, Eldin, Carole, Finance, Julie, Vieira, Vera Esteves, Tissot-Dupont, Hervé Tissot, Honoré, Stéphane, Stein, Andreas, Million, Matthieu, Colson, Philippe, La Scola, Bernard, Veit, Véronique, Jacquier, Alexis, Deharo, Jean-Claude, Drancourt, Michel, Fournier, Pierre Edouard, Rolain, Jean-Marc, Brouqui, Philippe, Raoult, Didier·2020·Travel Medicine and Infectious Disease

Abstract

BACKGROUND: We need an effective treatment to cure COVID-19 patients and to decrease virus carriage duration. METHODS: We conducted an uncontrolled, non-comparative, observational study in a cohort of 80 relatively mildly infected inpatients treated with a combination of hydroxychloroquine and azithromycin over a period of at least three days, with three main measurements: clinical outcome, contagiousness as assessed by PCR and culture, and length of stay in infectious disease unit (IDU). RESULTS: All patients improved clinically except one 86 year-old patient who died, and one 74 year-old patient still in intensive care. A rapid fall of nasopharyngeal viral load was noted, with 83% negative at Day7, and 93% at Day8. Virus cultures from patient respiratory samples were negative in 97.5% of patients at Day5. Consequently patients were able to be rapidly discharged from IDU with a mean length of stay of five days. CONCLUSION: We believe there is urgency to evaluate the effectiveness of this potentially-life saving therapeutic strategy at a larger scale, both to treat and cure patients at an early stage before irreversible severe respiratory complications take hold and to decrease duration of carriage and avoid the spread of the disease. Furthermore, the cost of treatment is negligible.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.tmaid.2020.101663

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 25 references

Cited by

See all 765

Metadata

Authors
Gautret, P., Lagier, J.-C., Parola, P., Hoang, V. T., Meddeb, L., Sevestre, J., Mailhe, M., Doudier, B., Aubry, C., Amrane, S., Seng, P., Hocquart, M., Eldin, C., Finance, J., Vieira, V. E., Tissot-Dupont, H. T., Honoré, S., Stein, A., Million, M., Colson, P., La Scola, B., Veit, V., Jacquier, A., Deharo, J.-C., Drancourt, M., Fournier, P. E., Rolain, J.-M., Brouqui, P., & Raoult, D.
Venue
Travel Medicine and Infectious Disease
Publisher
Elsevier BV
Published
2020-03
Volume
34
Pages
101663
ISSN
1477-8939 (ISSN-L)
OpenAlex
W3015620943
Cited by
765
References
25
FWCI
22.21
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study. https://app.cochat.ai/papers/10.1016/j.tmaid.2020.101663
The paper
Gautret, P., Lagier, J.-C., Parola, P., Hoang, V. T., Meddeb, L., Sevestre, J., Mailhe, M., Doudier, B., Aubry, C., Amrane, S., Seng, P., Hocquart, M., Eldin, C., Finance, J., Vieira, V. E., Tissot-Dupont, H. T., Honoré, S., Stein, A., Million, M., . . . Raoult, D. (2020). Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study. Travel Medicine and Infectious Disease. https://doi.org/10.1016/j.tmaid.2020.101663

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.